Eli Lilly's Alzhiemer's Drug Shows Potential in Final Trials
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
The World Health Organization picked 2030 as a seemingly random stretch goal for finding a cure for the global scourge that is Alzheimer's Disease. Stunningly, it now looks like the medical industry might be on track to get it done.
On Wednesday, pharmaceutical giant Eli Lilly announced that its experimental drug, donanemab, slowed the progress of Alzheimer's in a final stage trial, setting the stage for FDA approval.
Source Fool.com
